Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 3.46% is 93% below its 5-year average of 50.50%, near the low end of its 5-year range (0.82%–104.72%).
As of the fiscal period ended Tuesday, June 30, 2026. 87.08% below its 12-month average of 26.80%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 3.46%.
DEBT TO ASSETS RATIO
3.46%
DEBT TO ASSETS RATIO AVG TTM
26.80%
DEBT TO ASSETS RATIO AVG 3Y
36.84%
DEBT TO ASSETS RATIO AVG 5Y
50.50%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-87.08%
CURRENT VS 3Y AVG
-90.60%
CURRENT VS 5Y AVG
-93.14%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 592 covered companies
CURRENT VS SECTOR MEDIAN
+3363.19%
vs the sector median at left
Inhibrx Biosciences Inc.
Market Cap
$1.39B
Debt to Assets Ratio
3.46%
TTM Avg
26.80%
3Y Avg
36.84%
5Y Avg
50.50%
Market Cap
$1.36B
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.45B
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.46B
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.32B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.31B
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibrx Biosciences Inc. (INBX) | $1.39B | 3.46% | 26.80% | 36.84% | 50.50% |
| AnaptysBio, Inc. (ANAB)vs › | $1.41B | 0.85% | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.36B | 0.01% | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.45B | 0.11% | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 0.02% | N/A | N/A | N/A |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.32B | 0.00% | N/A | N/A | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.31B | 0.11% | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.48B | 0.00% | N/A | N/A | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.49B | 0.25% | N/A | N/A | N/A |
Debt/Assets
3.5%
Debt/Equity
N/A
Current Ratio
5.07
Interest Coverage
-11.1x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 3.46% |
| 2026-03-31 | 3.21% |
| 2025-12-31 | 73.06% |
| 2025-09-30 | 3.94% |
| 2025-06-30 | 50.34% |
| 2025-03-31 | 43.90% |
| 2024-12-31 | 4.45% |
| 2024-09-30 | 0.82% |
| 2024-06-30 | 0.84% |
| 2024-03-31 | 73.08% |
| 2023-12-31 | 68.25% |
| 2023-09-30 | 55.63% |
| 2023-06-30 | 97.86% |
| 2023-03-31 | 81.17% |
| 2022-12-31 | 71.20% |
| 2022-09-30 | 104.72% |
| 2022-06-30 | 90.94% |
| 2022-03-31 | 71.62% |
| 2021-12-31 | 47.95% |
| 2021-09-30 | 59.74% |
| 2021-06-30 | 54.38% |
| 2021-03-31 | 29.95% |
| 2020-12-31 | 26.06% |
| 2020-09-30 | 13.09% |
| 2020-06-30 | 50.61% |
| 2020-03-31 | 255.32% |
| 2019-12-31 | 157.55% |
| 2019-06-30 | 82.95% |
| 2019-03-31 | 69.27% |
| 2018-12-31 | 95.09% |
| 2017-12-31 | 85.01% |
